

BIOSTATISTICAL REGRESSIONS AND REPORTING



ALEN DELIC, MS

ADAM DE HAVENON, MD, MS



WHAT IS REGRESSION



- Technique used to determine how a variable of interest, or a dependent variable, is affected by one or more independent variables
- Answers questions such as:
 - Which factors matter most?
 - Which can we ignore?
 - How do those factors interact with each other?
 - And, perhaps most importantly, how certain are we about all of these factors?


ENDOVASCULAR THERAPY FOR ACUTE STROKE WITH A LARGE ISCHEMIC REGION

- **BACKGROUND:** Endovascular therapy for acute ischemic stroke is generally avoided when the infarction is large, but the **effect of endovascular therapy with medical care as compared with medical care alone** for large strokes has not been well studied.
- **METHODS:** We conducted a multicenter, open-label, randomized clinical trial in Japan involving patients with occlusion of large cerebral vessels and sizable strokes on imaging... Patients were **randomly assigned** in a 1:1 ratio to receive **endovascular therapy with medical care or medical care alone**... The **primary outcome** was a modified Rankin scale score of 0 to 3 (on a scale from 0 to 6, with higher scores indicating greater disability) at 90 days.
- **RESULTS:** A total of 203 patients underwent randomization... The percentage of patients with a modified Rankin scale score of 0 to 3 at 90 days was 31.0% in the endovascular-therapy group and 12.7% in the medical-care group (**relative risk, 2.43**; 95% confidence interval [CI], 1.35 to 4.37; $P=0.002$). The ordinal shift across the range of modified Rankin scale scores **generally favored endovascular therapy**.
- **CONCLUSIONS:** Patients with large cerebral infarctions **had better functional outcomes with endovascular therapy** than with medical care alone but had more intracranial hemorrhages.



A RANDOMIZED TRIAL OF INTRAARTERIAL TREATMENT FOR ACUTE ISCHEMIC STROKE

- **BACKGROUND:** In patients with acute ischemic stroke caused by a proximal intracranial arterial occlusion, intraarterial treatment is highly effective for emergency revascularization. However, **proof of a beneficial effect on functional outcome is lacking.**
- **METHODS:** We randomly assigned eligible patients to either intraarterial treatment plus usual care or usual care alone. The primary outcome was the **modified Rankin scale score at 90 days**; this categorical scale measures functional outcome, with scores ranging from 0 (no symptoms) to 6 (death). The treatment effect was estimated with **ordinal logistic regression** as a common **odds ratio**, adjusted for prespecified prognostic factors.
- **RESULTS:** We enrolled 500 patients at 16 medical centers... The adjusted common **odds ratio was 1.67 (95% confidence interval [CI], 1.21 to 2.30).**
- **CONCLUSIONS:** In patients with acute ischemic stroke caused by a proximal intracranial occlusion of the anterior circulation, **intraarterial treatment administered within 6 hours after stroke onset was effective and safe.**



LINEAR REGRESSION RELIES ON A NUMBER OF ASSUMPTIONS



- Linear regression assumes that...
 - **Linearity** – the relationships between the predictors and the outcome variable should be linear
 - **Normality** – the errors should be normally distributed
 - **Homogeneity of variance** (homoscedasticity) – the error variance should be constant
 - **Independence** – individual observations don't depend on others
 - **Model specification** – the model should be properly specified

INTER-INDIVIDUAL VARIABILITY IN THE CAPACITY FOR MOTOR RECOVERY AFTER ISCHEMIC STROKE

- *Background.* Motor recovery after stroke is predicted only moderately by clinical variables, implying that there is still a substantial amount of unexplained, biologically meaningful variability in recovery.
- *Methods.* Forty-one patients with ischemic stroke were studied. Impairment was assessed using the upper extremity Fugl-Meyer Motor Score. Motor recovery was defined as **the change in the upper extremity Fugl-Meyer Motor Score from 24 to 72 hours after stroke to 3 or 6 months later.**
- Regression diagnostics included a **Kolmogorov-Smirnov test for Gaussian errors (Normality)** and a test for **outliers using Studentized deleted residuals.**
- Regression diagnostics demonstrated the existence of a subpopulation of **outliers with severe initial impairment** who show little recovery. When these outliers were **removed**, clinical variables were **good predictors** of recovery among the remaining patients, showing a tight proportional relationship to initial impairment.




Figure 2. Predicted versus observed Δ_{FM} for the regression model of Table 2. The line is the least-squares fit. The triangles indicate the outliers identified subsequently.




Figure 4. Predicted versus observed Δ_{FM} for the regression model of Table 3 (excluding the outliers). The line is the least-squares fit.

LINEAR REGRESSION DIAGNOSTICS



- Check for Normality
 - Normality of residuals is only required for valid hypothesis testing
 - Residual errors be identically and independently distributed
 - Graphically:
 - Kernel density plot
 - P-P or Q-Q plot
 - Statistically:
 - Shapiro-Wilk W test for normality
 - Looking for a non-significant P-value (>0.05)


LINEAR REGRESSION DIAGNOSTICS



- Check for Homoscedasticity
 - There should be no pattern to the residuals plotted against the fitted values
 - Graphically:
 - Plot residuals versus predicted values
 - Statistically:
 - White's test
 - Cook-Weisberg test for heteroskedasticity



Heteroscedasticity




LINEAR REGRESSION DIAGNOSTICS




- Check for Outliers
 - An observation that is substantially different than others
 - Can have a high impact on final results
 - Can look for outliers graphically and with use of residuals
 - Standardized residuals that exceed $-2/+2$ are potential outliers
 - DFBETA residuals: assesses how much influence a specific observation has
 - Boxplots with IQR rule

LINEAR REGRESSION DIAGNOSTICS



LINEAR REGRESSION DIAGNOSTICS



REGRESSION DIAGNOSTICS







- Check for multicollinearity
 - Two (or more) variables are near perfect linear combinations of one another
 - As degree of multicollinearity increases, model coefficients become unstable and SEs are inflated
 - Can assess multicollinearity by looking at the *variance inflation factor (vif)*
 - $VIFs > 10$ merit further investigation

WHAT IS SURVIVAL ANALYSIS



- Statistical methods for analyzing longitudinal data on the occurrence of events
- Events may include death, injury, onset of illness, recovery from illness (binary variables) or transition above or below the clinical threshold of a meaningful continuous variable (e.g. CD4 counts).
- Accommodates data from randomized clinical trial or cohort study design.



Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale

Anthony J. Furlan, M.D.,
Mark Reisman, M.D.,



Abstract

BACKGROUND

The prevalence of patent foramen ovale among patients with cryptogenic stroke is higher than that in the general population. Closure with a percutaneous device is often recommended in such patients, but it is not known whether this intervention reduces the risk of recurrent stroke.

METHODS


We conducted a multicenter, randomized, open-label trial of closure with a percutaneous device, as compared with medical therapy alone, in patients between 18 and 60 years of age who presented with a cryptogenic stroke or transient ischemic attack (TIA) and had a patent foramen ovale. The primary end point was a composite of stroke or transient ischemic attack during 2 years of follow-up, death from any cause during the first 30 days, or death from neurologic causes between 31 days and 2 years.

RESULTS

A total of 909 patients were enrolled in the trial. The cumulative incidence (Kaplan–Meier estimate) of the primary end point was 5.5% in the closure group (447 patients) as compared with 6.8% in the medical-therapy group (462 patients) (adjusted hazard ratio, 0.78; 95% confidence interval, 0.45 to 1.35; $P=0.37$). The respective rates were 2.9% and 3.1% for stroke ($P=0.79$) and 3.1% and 4.1% for TIA ($P=0.44$). No deaths occurred by 30 days in either group, and there were no deaths from neurologic causes during the 2-year follow-up period. A cause other than paradoxical embolism was usually apparent in patients with recurrent neurologic events.

CONCLUSIONS

In patients with cryptogenic stroke or TIA who had a patent foramen ovale, closure with a device did not offer a greater benefit than medical therapy alone for the prevention of recurrent stroke or TIA. (Funded by NMT Medical; ClinicalTrials.gov number, [NCT00201461](#).)



| No. at Risk | 447 | 411 | 406 | 399 | 392 | 389 | 384 | 380 | 254 |
|-----------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Closure | 447 | 411 | 406 | 399 | 392 | 389 | 384 | 380 | 254 |
| Medical therapy | 462 | 421 | 405 | 388 | 378 | 365 | 359 | 356 | 242 |

Figure 1. Kaplan–Meier Curve of Time to Primary End Point through 2 Years of Follow-up in the Closure and Medical-Therapy Groups.

Using Ultrasound and Inflammation to Improve Prediction of Ischemic Stroke: A Secondary Analysis of the Multi-Ethnic Study of Atherosclerosis

Hediyeh Baradaran
Alen Delic
Adam de Havenon



- **Background.** We examined the relationship between baseline ultrasound and inflammation measurements and subsequent primary ischemic stroke risk.
- **Methods.** Multi-Ethnic Study of Atherosclerosis (MESA) was used. primary outcome is the incident ischemic stroke during follow-up. The predictor variables are 9 carotid ultrasound-derived measurements and 6 serum inflammation measurements from the baseline study visit. We fit Cox regression models to the outcome of ischemic stroke.
- In the Cox models, we found that carotid distensibility (CD), carotid stenosis (CS), and serum interleukin-6 (IL-6) were associated with incident stroke. Adding tertiles of CD, IL-6, and categories of CS to a baseline model that included traditional clinical vascular risk factors resulted in a better model fit than traditional risk factors alone as indicated by goodness-of-fit statistics (AIC, NRI, IDI)
- Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were used to assess improvement in prediction with addition predictors. Goodness-of-fit of the baseline and new model was assessed by evaluating results from a likelihood ratio test and AIC

Effect of adding individual serum inflammatory marker variables to the baseline Cox proportional hazards model

| Serum inflammatory marker | Hazard ratio ¹ | 95% CI | p value |
|----------------------------------|---------------------------|------------------|--------------|
| CRP | 1.01 | 0.98–1.04 | 0.433 |
| Fibrinogen antigen (mg/dL) | 1.00 | 1.00–1.00 | 0.192 |
| Plasmin-antiplasmin complex (nM) | 1.03 | 0.97–1.10 | 0.324 |
| D-Dimer (µg/mL) | 0.95 | 0.71–1.26 | 0.704 |
| Factor VIII (%) | 1.00 | 1.00–1.01 | 0.608 |
| IL-6 (pg/mL) | <i>1.21</i> | <i>1.08–1.36</i> | <i>0.001</i> |

Italicized variables are statistically significant. CRP, C-reactive protein.

¹Adjusted for baseline age, diabetes, hypertension, total cholesterol, smoking, and systolic blood pressure ≥ 160 mm Hg.

OBJECTIVES OF SURVIVAL ANALYSIS



- Estimate time-to-event for a group of individuals, such as time until stroke for a group of patients.
- Compare time-to-event between two or more groups, such as treated vs. placebo patients in an RCT.
- Assess the relationship of co-variables to time-to-event, such as: does weight, age, race, smoking status, etc... affect survival time of patients?

BENEFITS OF SURVIVAL ANALYSIS




- If we analyzed the mean time-to-event using a linear regression/t-test, we would be ignoring a concept called *censoring*
 - Censoring is when a patient is lost to follow up or experiences an event that stops their inclusion in the trial (such as death if the main outcome was stroke)

CENSORING



Figure 1. A visualization for the meaning of right censoring.



HAZARD RATE & SURVIVAL PROBABILITY




- The hazard rate is the probability that an individual will experience an event at time t while that individual is at risk for having an event
 - If the hazard rate is constant over time and it was equal to 1.5 for example this would mean that one would expect 1.5 events to occur in a time interval that is one unit long
- Survival probability is the probability that an individual survives from the time origin to a specified future time
 - Or flip the interpretation and consider failure probability

HAZARD RATE




- The hazard rate is the probability that an individual will experience an event at time t while that individual is at risk for having an event



SURVIVAL PROBABILITY & KAPLAN-MEIER PLOT



- Can show survival (KP) curves by different groupings (i.e treatment v placebo)
- Can test for significant differences in survival curves using Log-Rank test
 - P-value < 0.05 indicates significant difference at 0.05 alpha level




ONE-YEAR RISK OF STROKE AFTER TRANSIENT ISCHEMIC ATTACK OR MINOR STROKE

Figure 2. Unadjusted Kaplan–Meier Event Curves for Stroke Recurrence from the Time of the Qualifying Event to 1 Year.

Scores on the ABCD² stroke risk scale range from 0 to 7, with higher scores indicating a greater risk of stroke; an age of 60 years or older, a blood-pressure level of 140/90 mm Hg or higher, a clinical finding of unilateral weakness or speech impairment, a duration of symptoms of 10 to 59 minutes, and diabetes are each assigned 1 point, and a duration of symptoms of 60 minutes or more is assigned 2 points. The Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification indicates the probable cause of the initial transient ischemic attack (TIA) or stroke; the five main categories are large-artery atherosclerosis, cardioembolism, small-vessel occlusion, other determined cause, and undetermined cause.


A Rate of Recurrent Stroke According to Time from Symptom Onset to Evaluation by Stroke Specialist



No. at Risk

| | | | | | |
|-----------|------|------|------|------|------|
| ≤24 hours | 3593 | 3289 | 3101 | 3067 | 2965 |
| >24 hours | 990 | 926 | 888 | 881 | 850 |


B Rate of Recurrent Stroke According to ABCD² Stroke Risk Score



No. at Risk

| | | | | | |
|-----------------|------|------|------|------|------|
| Score of 0–3 | 1294 | 1221 | 1175 | 1166 | 1063 |
| Score of 4 or 5 | 1851 | 1701 | 1633 | 1625 | 1484 |
| Score of 6 or 7 | 745 | 684 | 657 | 642 | 596 |


C Rate of Recurrent Stroke According to Finding on Brain Imaging



No. at Risk

| | | | | | |
|----------------------------|------|------|------|------|------|
| No acute infarction | 2946 | 2699 | 2570 | 2542 | 2289 |
| Single acute infarction | 995 | 926 | 894 | 885 | 821 |
| Multiple acute infarctions | 481 | 414 | 397 | 394 | 357 |

D Rate of Recurrent Stroke According to Cause of TIA or Minor Stroke (TOAST Classification)



No. at Risk

| | | | | | |
|------------------------------|------|------|------|------|------|
| Large-artery atherosclerosis | 987 | 892 | 863 | 853 | 799 |
| Small-vessel occlusion | 983 | 905 | 862 | 857 | 790 |
| Cardioembolism | 641 | 584 | 570 | 561 | 494 |
| Other determined cause | 244 | 214 | 205 | 198 | 184 |
| Undetermined cause | 1354 | 1263 | 1206 | 1199 | 1085 |

HAZARD RATE & COX PROPORTIONAL HAZARDS MODEL



- Regression model used for investigating the association between the survival time of patients and one or more predictor variables.
- KP curves and log-rank test useful for *univariate* models with categorical predictor
 - Good first in data exploration
- Cox model benefits
 - Can fit multiple predictor variables
 - Use both quantitative and qualitative
 - More inference possibilities

HAZARD RATE & COX PROPORTIONAL HAZARDS MODEL



- In Cox models, we are estimating the Hazard Ratio for each covariate of the model
 - $HR = 1$: No effect
 - $HR < 1$: Reduction in the hazard
 - $HR > 1$: Increase in Hazard
- Example: A $HR > 1$ indicates a covariate that is positively associated with the event probability, and thus negatively associated with the length of survival.

SUBCLINICAL ATRIAL FIBRILLATION AND THE RISK OF STROKE

- **BACKGROUND:** We evaluated whether subclinical episodes of rapid atrial rate detected by implanted devices were **associated with an increased risk of ischemic stroke** in patients who did not have other evidence of atrial fibrillation.
- **METHODS:** We enrolled 2580 patients, 65 years of age or older, with hypertension and no history of atrial fibrillation, in whom a pacemaker or defibrillator had recently been implanted. We monitored the patients for 3 months and... **followed them for a mean of 2.5 years for the primary outcome of ischemic stroke or systemic embolism.** Patients with pacemakers were **randomly assigned** to receive or not to receive continuous atrial overdrive pacing.
- **RESULTS:** Subclinical atrial tachyarrhythmias were associated with an increased risk of clinical atrial fibrillation (**hazard ratio, 5.56**; 95% confidence interval [CI], 3.78 to 8.17; $P<0.001$) and of ischemic stroke or systemic embolism (**hazard ratio, 2.49**; 95% CI, 1.28 to 4.85; $P=0.007$). Subclinical atrial tachyarrhythmias remained predictive of the primary outcome after adjustment for predictors of stroke (**hazard ratio, 2.50**; 95% CI, 1.28 to 4.89; $P=0.008$). Continuous atrial overdrive pacing **did not prevent atrial fibrillation.**




Table 3. Risk of Ischemic Stroke or Systemic Embolism after the 3-Month Visit, According to Baseline CHADS₂ Score and According to Whether Subclinical Atrial Tachyarrhythmias Were or Were Not Detected between Enrollment and the 3-Month Visit.

| CHADS ₂ Score | No. of Patients | Subclinical Atrial Tachyarrhythmias between Enrollment and 3 Months | | | | | | Hazard Ratio for Ischemic Stroke or Systemic Embolism with Subclinical Atrial Tachyarrhythmias (95% CI)* |
|--------------------------|-----------------|---|----------------------|-------------|------------------------|----------------------|-------------|--|
| | | Present | | | Absent | | | |
| | | <i>no. of patients</i> | <i>no. of events</i> | <i>%/yr</i> | <i>no. of patients</i> | <i>no. of events</i> | <i>%/yr</i> | |
| 1 | 600 | 68 | 1 | 0.56 | 532 | 4 | 0.28 | 2.11 (0.23–18.9) |
| 2 | 1129 | 119 | 4 | 1.29 | 1010 | 18 | 0.70 | 1.83 (0.62–5.40) |
| >2 | 848 | 72 | 6 | 3.78 | 776 | 18 | 0.97 | 3.93 (1.55–9.95) |

SURVIVAL ANALYSIS MODEL DIAGNOSTICS/ASSUMPTIONS



- One of the main assumptions of the Cox proportional hazard model is proportionality
 - The survival functions are approximately parallel
- This assumption is tested by looking at the Schoenfeld residuals
 - Statistical test: a p-value above 0.05 indicates no evidence that we're violating the assumption
- Can also use Cox-Snell residuals to graphically observe the fit of the model
 - Looking for parallel lines



```
. estat phtest, detail
```

```
Test of proportional-hazards assumption
```

```
Time function: Analysis time
```

| | rho | chi2 | df | Prob>chi2 |
|-------------|----------|-------|----|-----------|
| sbp | -0.04375 | 2.83 | 1 | 0.0927 |
| scl | -0.04810 | 3.54 | 1 | 0.0600 |
| age | -0.11937 | 20.46 | 1 | 0.0000 |
| bmi | -0.00276 | 0.01 | 1 | 0.9164 |
| female | 0.10301 | 15.58 | 1 | 0.0001 |
| Global test | | 46.97 | 5 | 0.0000 |

- When proportionality is not met for a variable, you can stratify the model on that variable i.e have one model each for males and females and then aggregate the results

COX SNELL RESIDUALS

